Rieder Michael J, Elzagallaai Abdelbaset A
Division of Paediatric Clinical Pharmacology, Department of Paediatrics, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Department of Physiology and Pharmacology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Methods Mol Biol. 2022;2547:569-593. doi: 10.1007/978-1-0716-2573-6_20.
Historically genetics has not been considered when prescribing drugs for children. However, it is clear that genetics are not only an important determinant of disease in children but also of drug response for many important drugs that are core agents used in the therapy of common problems in children. Advances in therapy and in the ethical construct of children's research have made pharmacogenomic assessment for children much easier to pursue. It is likely that pharmacogenomics will become part of the therapeutic decision-making process for children, notably in areas such as childhood cancer where weighing benefits and risks of therapy is crucial.
从历史上看，在给儿童开药时并未考虑遗传学因素。然而，很明显，遗传学不仅是儿童疾病的重要决定因素，也是许多重要药物反应的决定因素，这些药物是治疗儿童常见问题的核心药物。治疗方法的进步以及儿童研究伦理结构的完善，使得对儿童进行药物基因组学评估变得更加容易。药物基因组学很可能会成为儿童治疗决策过程的一部分，尤其是在儿童癌症等领域，在这些领域权衡治疗的益处和风险至关重要。
